

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024165 A1

(51) International Patent Classification⁷: **A61K 31/66**,
31/405, A61P 35/00, A61K 45/06

[AU/AU]; 11 Albion Street, South Yarra, Victoria 3141 (AU).

(21) International Application Number:
PCT/EP2003/009972

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date:
8 September 2003 (08.09.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0220885.8 9 September 2002 (09.09.2002) GB

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BAULCH-BROWN, Cindy, Maree** [AU/AU]; 38 Teatree Drive, South Morang, Victoria 3752 (AU). **SPENCER, Andrew**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION THERAPY COMPRISING A BISPHOSPHONATE AND A HMG-COA REDUCTASE INHIBITOR

(57) Abstract: A pharmaceutical composition for treatment of malignancies, in particular multiple myeloma (MM), comprises in combination a bisphosphonate, e.g. zoledronic acid or a salt or ester, and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use. Also provided is a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an HMG-CoA reductase inhibitor.



WO 2004/024165 A1

- 1 -

COMBINATION THERAPY COMPRISING A BISPHOSPHONATE AND A HMG-COA REDUCTASE INHIBITOR

This invention relates to bisphosphonates, in particular to new pharmaceutical uses of, and compositions containing, bisphosphonates.

Bisphosphonates are widely used to inhibit osteoclast activity in a variety of both benign and malignant diseases, which involve excessive or inappropriate bone resorption. These pyrophosphate analogs not only reduce the occurrence of skeletal related events but they also provide patients with clinical benefit and improve survival. Bisphosphonates are able to prevent bone resorption *in vivo*; the therapeutic efficacy of bisphosphonates has been demonstrated in the treatment of osteoporosis, osteopenia, Paget's disease of bone, tumour-induced hypercalcemia (TIH) and, more recently, bone metastases (BM) and multiple myeloma (MM) (for review see Fleisch H 1997 Bisphosphonates clinical. In Bisphosphonates in Bone Disease. From the Laboratory to the Patient. Eds: The Parthenon Publishing Group, New York/London pp 68-163). The mechanisms by which bisphosphonates inhibit bone resorption are still not completely understood and seem to vary according to the bisphosphonates studied. Bisphosphonates have been shown to bind strongly to the hydroxyapatite crystals of bone, to reduce bone turn-over and resorption, to decrease the levels of hydroxyproline or alkaline phosphatase in the blood, and in addition to inhibit the formation, recruitment, activation and the activity of osteoclasts.

Recent studies have also shown that some bisphosphonates may have a direct effect on tumour cells. Thus for example it has been found that relatively high concentrations of bisphosphonates, including zoledronate, induce apoptosis of breast and prostate carcinoma and myeloma cells in vitro (Senaratne et al. Br. J. Cancer, 82: 1459-1468, 2000; Lee et al., Cancer Res., 61: 2602-2608, 2001, Shipman et al. Br. J. Cancer, 98: 665-672 (1997).

The statins, such as fluvastatin (Lescol, Novartis Pharma AG) are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, i.e. HMG-CoA reductase inhibitors, and are widely used as cholesterol lowering agents.

- 2 -

It has now been found that if certain types of bisphosphonates are used in combination with certain types of HMG-CoA reductase inhibitors to treat human myeloma cells in vitro, that the bisphosphonate and HMG-CoA reductase inhibitor act synergistically to inhibit myeloma cell proliferation and induce myeloma cell apoptosis. Additionally it has been found that the HMG-CoA reductase inhibitor fluvastatin on its own inhibits proliferation and induces apoptosis of human myeloma cells in vitro.

Accordingly the present invention provides a pharmaceutical composition for treatment of malignancies, which comprises in combination a bisphosphonate and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use.

Further the invention provides the use of an HMG-CoA reductase inhibitor for the preparation of a medicament, for use in combination with a bisphosphonate for treatment of a malignant disease.

In the alternative the invention provides use of a bisphosphonate for the preparation of a medicament for use in combination with an HMG-CoA reductase inhibitor for treatment of a malignant disease.

In a further aspect the invention provides a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an HMG-CoA reductase inhibitor.

Yet further the invention provides use of an HMG-CoA reductase inhibitor in combination with a bisphosphonate to inhibit cancer cell growth or induce cancer cell apoptosis.

Accordingly also the present invention further provides a pharmaceutical composition for inhibiting cancer cell growth or inducing cancer cell apoptosis which comprises in

- 3 -

combination a bisphosphonate and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use.

Further the invention provides the use of a bisphosphonate for the preparation of a medicament, for use in combination with an HMG-CoA reductase inhibitor for inhibiting cancer cell growth or inducing cancer cell apoptosis.

In accordance with the present invention it has been found that HMG-CoA reductase inhibitors on their own inhibit cancer cell growth or induce cancer cell apoptosis.

Thus in yet further embodiments the invention provides:
a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of an HMG-CoA reductase inhibitor; and
use of an HMG-CoA reductase inhibitor for the preparation of an anti-cancer medicament.

In the present description the term "treatment" includes both prophylactic or preventative treatment as well as curative or disease modifying treatment, including treatment of patients at risk of contracting the disease or suspected to have contracted the disease as well as ill patients.

The invention is generally applicable to the treatment of malignant diseases for which bisphosphonate treatment is indicated. Thus typically the disease is a malignant disease which is associated with the development of bone metastases or excessive bone resorption. Examples of such diseases include cancers, such as breast and prostate cancers, multiple myeloma (MM), tumour induced hypertension (TIH) and similar diseases and conditions. In particular the invention is applicable to the treatment of multiple myeloma (MM) and associated bone metastases (BM).


The compositions, uses and methods of the present invention represent an improvement to existing therapy of malignant diseases in which bisphosphonates are used, e.g. to prevent or

- 4 -

inhibit development of bone metastases or excessive bone resorption, and in which bisphosphonate treatment also inhibits cancer cell growth or induces cancer cell apoptosis. The combination of a bisphosphonate with an HMG-CoA reductase inhibitor advantageously gives rise to enhanced, advantageously synergistic, levels of cancer cell growth inhibition or cancer cell apoptosis, e.g. inhibition proliferation and induction of apoptosis of human myeloma cells.

The bisphosphonates for use in the present invention are preferably N-bisphosphonates.

For the purposes of the present description an N-bisphosphonate is a compound which in addition to the characteristic geminal bisphosphate moiety comprises a nitrogen containing side chain, e.g. a compound of formula I



wherein

X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C₁-C₄ alkyl, or alkanoyl;

R is hydrogen or C₁-C₄ alkyl and


Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles), and pharmaceutically acceptable salts thereof or any hydrate thereof.

Thus, for example, suitable N-bisphosphonates for use in the invention may include the following compounds or a pharmaceutically acceptable salt thereof, or any hydrate thereof: 3-amino-1-hydroxypropane-1,1-diphosphonic acid (pamidronic acid), e.g. pamidronate (APD); 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid, e.g. dimethyl-APD; 4-

- 5 -

amino-1-hydroxybutane-1,1-diphosphonic acid (alendronic acid), e.g. alendronate; 1-hydroxy-3-(methylpentylamino)-propylidene-bisphosphonic acid, ibandronic acid, e.g. ibandronate; 6-amino-1-hydroxyhexane-1,1-diphosphonic acid, e.g. amino-hexyl-BP; 3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-1,1-diphosphonic acid, e.g. methyl-pentyl-APD (= BM 21.0955); 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, e.g. zoledronic acid; 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid (risedronic acid), e.g. risedronate, including N-methyl pyridinium salts thereof, for example N-methyl pyridinium iodides such as NE-10244 or NE-10446; 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-1-yl)propane-1,1-diphosphonic acid, e.g. EB 1053 (Leo); 1-(N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid, e.g. FR 78844 (Fujisawa); 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, e.g. U-81581 (Upjohn); and 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid, e.g. YM 529.

In one embodiment a particularly preferred N-bisphosphonate for use in the invention comprises a compound of Formula II



wherein

Het is an imidazole, oxazole, isoxazole, oxadiazole, thiazole, thiadiazole, pyridine, 1,2,3-triazole, 1,2,4-triazole or benzimidazole radical, which is optionally substituted by alkyl, alkoxy, halogen, hydroxyl, carboxyl, an amino group optionally substituted by alkyl or alkanoyl radicals or a benzyl radical optionally substituted by alkyl, nitro, amino or aminoalkyl;

A is a straight-chained or branched, saturated or unsaturated hydrocarbon moiety containing from 1 to 8 carbon atoms;


- 6 -

X' is a hydrogen atom, optionally substituted by alkanoyl, or an amino group optionally substituted by alkyl or alkanoyl radicals, and

R is a hydrogen atom or an alkyl radical,

and the pharmacologically acceptable salts thereof.

In a further embodiment a particularly preferred bisphosphonate for use in the invention comprises a compound of Formula III



wherein

Het' is a substituted or unsubstituted heteroaromatic five-membered ring selected from the group consisting of imidazolyl, imidazoliny, isoxazolyl, oxazolyl, oxazoliny, thiazolyl, thiazoliny, triazolyl, oxadiazolyl and thiadiazolyl wherein said ring can be partly hydrogenated and wherein said substituents are selected from at least one of the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, phenyl, cyclohexyl, cyclohexylmethyl, halogen and amino and wherein two adjacent alkyl substituents of Het can together form a second ring;

Y is hydrogen or C₁-C₄ alkyl;


X'' is hydrogen, hydroxyl, amino, or an amino group substituted by C₁-C₄ alkyl, and

R is hydrogen or C₁-C₄ alkyl;

as well as the pharmacologically acceptable salts and isomers thereof.

In a yet further embodiment a particularly preferred bisphosphonate for use in the invention comprises a compound of Formula IV

- 7 -



wherein

Het''' is an imidazolyl, 2H-1,2,3-, 1H-1,2,4- or 4H-1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl or thiadiazolyl radical which is unsubstituted or C-mono- or di-substituted by lower alkyl, by lower alkoxy, by phenyl which may in turn be mono- or disubstituted by lower alkyl, lower alkoxy and/or halogen, by hydroxy, by di-lower alkylamino, by lower alkylthio and/or by halogen and is N-substituted at a substitutable N-atom by lower alkyl or by phenyl-lower alkyl which may in turn be mono- or di-substituted in the phenyl moiety by lower alkyl, lower alkoxy and/or halogen, and

R2 is hydrogen, hydroxy, amino, lower alkylthio or halogen,

lower radicals having up to and including 7 C-atoms,

or a pharmacologically acceptable salt thereof.

Examples of particularly preferred N-bisphosphonates for use in the invention are:

2-(1-Methylimidazol-2-yl)-1-hydroxyethane-1,1-diphosphonic acid;

2-(1-Benzylimidazol-2-yl)-1-hydroxyethane-1,1-diphosphonic acid;

2-(1-Methylimidazol-4-yl)-1-hydroxyethane-1,1-diphosphonic acid;

1- Amino-2-(1-methylimidazol-4-yl)ethane-1,1-diphosphonic acid;

1- Amino-2-(1-benzylimidazol-4-yl)ethane-1,1-diphosphonic acid;

2-(1-Methylimidazol-2-yl)ethane-1,1-diphosphonic acid;

2-(1-Benzylimidazol-2-yl)ethane-1,1-diphosphonic acid;

2-(Imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid;

2-(Imidazol-1-yl)ethane-1,1-diphosphonic acid;

2-(4H-1,2,4-triazol-4-yl)-1-hydroxyethane-1,1-diphosphonic acid;

- 8 -

2-(Thiazol-2-yl)ethane-1,1-diphosphonic acid;
2-(Imidazol-2-yl)ethane-1,1-diphosphonic acid;
2-(2-Methylimidazol-4(5)-yl)ethane-1,1-diphosphonic acid;
2-(2-Phenylimidazol-4(5)-yl)ethane-1,1-diphosphonic acid;
2-(4,5-Dimethylimidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid, and
2-(2-Methylimidazol-4(5)-yl)-1-hydroxyethane-1,1-diphosphonic acid,
and pharmacologically acceptable salts thereof.

The most preferred N-bisphosphonate for use in the invention is 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

All the N-bisphosphonic acid derivatives mentioned above are well known from the literature. This includes their manufacture (see e.g. EP-A-513760, pp. 13-48). For example, 3-amino-1-hydroxypropane-1,1-diphosphonic acid is prepared as described e.g. in US patent 3,962,432 as well as the disodium salt as in US patents 4,639,338 and 4,711,880, and 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid is prepared as described e.g. in US patent 4,939,130. See also US patents 4,777,163 and 4,687,767.

The N-bisphosphonates may be used in the form of an isomer or of a mixture of isomers where appropriate, typically as optical isomers such as enantiomers or diastereoisomers or geometric isomers, typically cis-trans isomers. The optical isomers are obtained in the form of the pure antipodes and/or as racemates.

The N-bisphosphonates can also be used in the form of their hydrates or include other solvents used for their crystallisation.

The HMG-CoA reductase inhibitors used in the pharmaceutical compositions and treatment methods of the present invention are preferably statins, including for example, atorvastatin,

cerivastatin, nisvastatin, pitavastatin, pravastatin, simvastatin, fluvastatin and similar compounds and salts and esters thereof.

In particular the HMG-CoA reductase inhibitor is fluvastatin or a related compound, such as the HMG-CoA reductase inhibitors described in EP 0 114 027B, US4,739,073 and US5,354,772, and pharmaceutically acceptable salts and esters thereof.

Pharmacologically acceptable salts of bisphosphonates and HMG-CoA reductase inhibitors are preferably salts with bases, conveniently metal salts derived from groups Ia, Ib, IIa and IIb of the Periodic Table of the Elements, including alkali metal salts, e.g. potassium and especially sodium salts, or alkaline earth metal salts, preferably calcium or magnesium salts, and also ammonium salts with ammonia or organic amines.

Especially preferred pharmaceutically acceptable salts of the N-bisphosphonates are those where one, two, three or four, in particular one or two, of the acidic hydrogens of the bisphosphonic acid are replaced by a pharmaceutically acceptable cation, in particular sodium, potassium or ammonium, in first instance sodium.

A very preferred group of pharmaceutically acceptable salts of the N-bisphosphonates is characterized by having one acidic hydrogen and one pharmaceutically acceptable cation, especially sodium, in each of the phosphonic acid groups.

The Agents of the Invention, i.e. the HMG-CoA reductase inhibitor and the bisphosphonate are preferably used in the form of pharmaceutical preparations that contain the relevant therapeutically effective amount of each active ingredient (either separately or in combination) optionally together with or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable for administration. The HMG-CoA REDUCTASE inhibitor and bisphosphonate active ingredients may be present in the same pharmaceutical compositions, e.g. as a fixed combinations, though are preferably in separate pharmaceutical compositions. Thus the active ingredients may be administered at the

- 10 -

same time (e.g. simultaneously) or at different times (e.g. sequentially) and over different periods of time, which may be separate from one another or overlapping.

The N-bisphosphonates are preferably used in the form of pharmaceutical compositions that contain a therapeutically effective amount of active ingredient optionally together with or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable for administration.

The N-bisphosphonate pharmaceutical compositions may be, for example, compositions for enteral, such as oral, rectal, aerosol inhalation or nasal administration, compositions for parenteral, such as intravenous or subcutaneous administration, or compositions for transdermal administration (e.g. passive or iontophoretic).

Preferably, the N-bisphosphonate pharmaceutical compositions are adapted to oral or parenteral (especially intravenous, intra-arterial or transdermal) administration. Intravenous and oral, first and foremost intravenous, administration is considered to be of particular importance. Preferably the N-bisphosphonate active ingredient is in a parenteral form, most preferably an intravenous form.

The particular mode of administration and the dosage may be selected by the attending physician taking into account the particulars of the patient, especially age, weight, life style, activity level, and disease state as appropriate. Most preferably, however, the N-bisphosphonate is administered intravenously.

The dosage of the N-bisphosphonate for use in the invention may depend on various factors, such as effectiveness and duration of action of the active ingredient, mode of administration, warm-blooded species, and/or sex, age, weight and individual condition of the warm-blooded animal.

- 11 -

Normally the dosage is such that a single dose of the bisphosphonate active ingredient from 0.002 – 20.0 mg/kg, especially 0.01 – 10.0 mg/kg, is administered to a warm-blooded animal weighing approximately 75kg. If desired, this dose may also be taken in several, optionally equal, partial doses.

"mg/kg" means mg drug per kg body weight of the mammal - including man - to be treated.

The HMG-CoA reductase pharmaceutical compositions may be, for example, compositions for enteral, such as oral, rectal, aerosol inhalation or nasal administration, compositions for parenteral, such as intravenous or subcutaneous administration, or compositions for transdermal administration (e.g. passive or iontophoretic).

Preferably, the HMG-CoA reductase pharmaceutical compositions are adapted to oral or parenteral (especially oral) administration. Preferably the HMG-CoA reductase inhibitor active ingredient is in oral form.

The particular mode of administration and the dosage may be selected by the attending physician taking into account the particulars of the patient, especially age, weight, life style, activity level, etc .

The dosage of the Agents of the Invention may depend on various factors, such as effectiveness and duration of action of the active ingredient, mode of administration, warm-blooded species, and/or sex, age, weight and individual condition of the warm-blooded animal.

The pharmacologically active compounds of the invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or

glycine; b) lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders e.g. magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g. starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.

Tablets may be either film coated or enteric coated according to methods known in the art.

Suitable formulations for transdermal application include an effective amount of a compound of the invention with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

Suitable formulations for topical application, e.g. to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, for example, for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g. for the treatment of skin cancer, for example, for prophylactic use in creams, lotions sprays and the like

The dosage of HMG-CoA reductase inhibitor administered is dependent on the species of warm-blooded animal (mammal), the body weight, age and individual condition, and on the form of administration. A unit dosage for oral administration to a mammal of about 50 to 70 kg may contain between about 5 and 1000 mg, e.g. from 100-800 mg, preferably 50-200 mg of the active ingredient.

HMG-CoA reductase inhibitor formulations in single dose unit form contain preferably from about 1% to about 90%, and formulations not in single dose unit form contain preferably from about 0.1% to about 50%, of the active ingredient. Single dose unit forms such as capsules, tablets or dragées contain e.g. from about 1mg to about 1000mg of the active ingredient.

HMG-CoA reductase inhibitor pharmaceutical preparations for enteral and parenteral administration are, for example, those in dosage unit forms, such as dragées, tablets or capsules and also ampoules. They are prepared in a manner known *per se*, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes. For example, pharmaceutical preparations for oral administration can be obtained by combining the active ingredient with solid carriers, where appropriate granulating a resulting mixture, and processing the mixture or granulate, if desired or necessary after the addition of suitable adjuncts, into tablets or dragée cores.

Preferred formulations for the HMG-CoA reductase inhibitors are described in GB 2,262,229A and US5,356,896.

Other orally administrable pharmaceutical preparations are dry-filled capsules made of gelatin, and also soft, sealed capsules made of gelatin and a plasticiser, such as glycerol or sorbitol. The dry-filled capsules may contain the active ingredient in the form of a granulate, for example in admixture with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and, where appropriate, stabilisers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable liquids, such as

fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilisers to be added.

Parenteral formulations are especially injectable fluids that are effective in various manners, such as intravenously, intramuscularly, intraperitoneally, intranasally, intradermally or subcutaneously. Such fluids are preferably isotonic aqueous solutions or suspensions which can be prepared before use, for example from lyophilised preparations which contain the active ingredient alone or together with a pharmaceutically acceptable carrier. The pharmaceutical preparations may be sterilised and/or contain adjuncts, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.

Suitable formulations for transdermal application include an effective amount of the active ingredient with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. Characteristically, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the active ingredient of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

In preferred embodiments, in view of the synergistic activity of the bisphosphonates and HMG-CoA reductase inhibitors, lower doses of both compounds may be used than would be the case if the bisphosphonate or HMG-CoA reductase inhibitor were used as sole treatment.

The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon.

EXAMPLES

A. Formulation Examples

Example 1

Wet granulated tablet composition

<u>Amount per tablet</u>		<u>Ingredient</u>
25	mg	HMG-CoA reductase inhibitor
79.7	mg	Microcrystalline cellulose
79.7	mg	Lactose monohydrate
6	mg	Hydroxypropyl cellulose
8	mg	Croscarmellose sodium
0.6	mg	Iron oxide
1	mg	Magnesium stearate

Tablet dose strengths of between 5 and 125 mg can be accommodated by varying total weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose: lactose monohydrate.

Example 2

Directly compressed tablet composition

<u>Amount per tablet</u>		<u>Ingredient</u>
25	mg	HMG-CoA reductase inhibitor
106.9	mg	Microcrystalline cellulose
106.9	mg	Lactose anhydrate
7.5	mg	Croscarmellose sodium
3.7	mg	Magnesium stearate

- 16 -

Tablet dose strengths of between 5 and 125 mg can be accommodated by varying total tablet weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose:lactose monohydrate.

Example 3

Hard gelatine capsule composition

<u>Amount per capsule</u>	<u>Ingredient</u>
25 mg	HMG-CoA reductase inhibitor
37 mg	Microcrystalline cellulose
37 mg	Lactose anhydrate
1 mg	Magnesium stearate
1 capsule	Hard gelatin capsule

Capsule dose strengths of between 1 and 50 mg can be accommodated by varying total fill weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose:lactose monohydrate.

Example 4

Oral solution

Amount per 5mL Ingredient

50 mg HMG-CoA reductase inhibitor
to 5 mL with Polyethylene oxide 400

Example 5

Oral suspension

Amount per 5mL dose Ingredient

- 17 -

101	mg	HMG-CoA reductase inhibitor
150	mg	Polyvinylpyrrolidone

Oral suspensionAmount per 5mL dose Ingredient

2.5	mg	Poly oxyethylene sorbitan monolaurate
10	mg	Benzoic acid
to 5 mL with sorbitol solution (70%)		

Suspension dose strengths of between 1 and 50 mg/5 ml can be accommodated by varying the ratio of the first two ingredients.

Example 6Intravenous infusionAmount per 200 mL dose Ingredient

1	mg	HMG-CoA reductase inhibitor
0.2	mg	Polyethylene oxide 400
1.8	mg	Sodium chloride
to 200 mL		Purified water

Example 7:

Capsules containing coated pellets of active ingredient, for example, disodium pamidronate pentahydrate, as active ingredient:

Core pellet:

active ingredient (ground)	197.3 mg
Microcrystalline cellulose	<u>52.7 mg</u>
(Avicel [®] PH 105)	250.0 mg

+ Inner coating:

- 18 -

Cellulose HP-M 603	10.0 mg
Polyethylene glycol	2.0 mg
Talc	<u>8.0 mg</u>
	270.0 mg

+ Gastric juice-resistant outer coating:

Eudragit [®] L 30 D (solid)	90.0 mg
Triethyl citrate	21.0 mg
Antifoam [®] AF	2.0 mg
Water	
Talc	<u>7.0 mg</u>
	390.0 mg

A mixture of disodium pamidronate with Avicel[®] PH 105 is moistened with water and kneaded, extruded and formed into spheres. The dried pellets are then successively coated in the fluidized bed with an inner coating, consisting of cellulose HP-M 603, polyethylene glycol (PEG) 8000 and talc, and the aqueous gastric juice-resistant coat, consisting of Eudragit[®] L 30 D, triethyl citrate and Antifoam[®] AF. The coated pellets are powdered with talc and filled into capsules (capsule size 0) by means of a commercial capsule filling machine, for example Höfliger and Karg.

Example 8:

Monolith adhesive transdermal system, containing as active ingredient, for example, 1-hydroxy-2-(imidazol-1-yl)-ethane-1,1-diphosphonic acid:

Composition:

polyisobutylene (PIB) 300	5.0 g
(Oppanol B1, BASF)	
PIB 35000	3.0 g

- 19 -

(Oppanol B10, BASF)	
PIB 1200000	9.0 g
(Oppanol B100, BASF)	
hydrogenated hydrocarbon resin	43.0 g
(Escorez 5320, Exxon)	
1-dodecylazacycloheptan-2-one	20.0 g
(Azone, Nelson Res., Irvine/CA)	
active ingredient	<u>20.0 g</u>
Total	100.0 g

Preparation:

The above components are together dissolved in 150 g of special boiling point petroleum fraction 100-125 by rolling on a roller gear bed. The solution is applied to a polyester film (Hostaphan, Kalle) by means of a spreading device using a 300mm doctor blade, giving a coating of about 75 g/m². After drying (15 minutes at 60°C), a silicone-treated polyester film (thickness 75 mm, Laufenberg) is applied as the peel-off film. The finished systems are punched out in sizes in the wanted form of from 5 to 30cm² using a punching tool. The complete systems are sealed individually in sachets of aluminised paper.

Example 9:

Vial containing 1.0 mg dry, lyophilized 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid (mixed sodium salts thereof). After dilution with 1 ml of water, a solution (concentration 1 mg/ml) for i.v. infusion is obtained.

Composition:

active ingredient (free diphosphonic acid)	1.0 mg
mannitol	46.0 mg
Trisodium citrate x 2 H ₂ O	ca. 3.0 mg

- 20 -

water	1 ml
-------	------

water for injection	1 ml .
---------------------	--------

In 1 ml of water, the active ingredient is titrated with trisodium citrate x 2 H₂O to pH 6.0. Then, the mannitol is added and the solution is lyophilized and the lyophilisate filled into a vial.

Example 10:

Ampoule containing active ingredient, for instance disodium pamidronate pentahydrate dissolved in water. The solution (concentration 3 mg/ml) is for i.v. infusion after dilution.

Composition:

active ingredient	19.73 mg
(≅ 5.0 mg of anhydrous active ingredient)	
mannitol	250 mg
water for injection	5 ml .

Example 11: In vitro analysis of growth inhibition and apoptosis induction in human myeloma cell lines by the 3'-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor fluvastatin alone and in combination with Zometa® (zoledronic acid)

We investigated the cytotoxic effect of the HMG-CoA reductase inhibitor fluvastatin on the human multiple myeloma cell lines LP-1, OPM-2, U266, NCI-H929 and RPMI-8226 in vitro using a tetrazolium reduction assay. After 3 days culture in the presence of 0 to 50 µM fluvastatin, the Promega MTS assay reagent was used to determine the level of inhibition of cell proliferation and/or cell death. Fluvastatin concentrations as low as 2.5 µM significantly inhibited proliferation of all cell lines except RPMI-8226 (p<0.05 by paired Student's t-test).

- 21 -

Concentrations of 25 μ M and 50 μ M significantly inhibited proliferation in all cell lines ($p < 0.05$ by paired Student's t-test), with inhibition at 50 μ M ranging from 45 to $>90\%$ for U266 to OPM-2.


Using the same assay we investigated whether the activity of fluvastatin against multiple myeloma in vitro could be enhanced by the addition of the bisphosphonate Zometa® (zoledronic acid). Using 80% cell inhibition as an end point, isobolograms were constructed to visualize the interaction between fluvastatin and Zometa®. Isobologram analysis indicated that fluvastatin and Zometa® synergistically to induce cell death in human myeloma cell lines. To illustrate this point, $>50 \mu$ M fluvastatin or $< 100 \mu$ M Zometa® alone was required to induce 80% cell death in the myeloma cell line LP-1 but the combination of 25 μ M fluvastatin and 0.21 μ M Zometa® had the same effect.

These initial data indicate that fluvastatin is a potential therapeutic agent for multiple myeloma both as a single agent and in combination with other agents such as Zometa®.

CLAIMS

1. A pharmaceutical composition for treatment of malignancies which comprises in combination a bisphosphonate and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use.
2. Use of an HMG-CoA reductase inhibitor for the preparation of a medicament, for use in combination with a bisphosphonate for treatment of a malignant disease.
3. Use of a bisphosphonate for the preparation of a medicament for use in combination with an HMG-CoA reductase inhibitor for treatment of a malignant disease.
4. Use of an HMG-CoA reductase inhibitor in combination with a bisphosphonate to inhibit cancer cell growth or induce cancer cell apoptosis.
5. A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an HMG-CoA reductase inhibitor.
6. A composition according to claim 1, use according to claims 2-4, or method according to claim 5 for the inhibition of cancer cell growth or induction cancer cell apoptosis.
7. A composition according to claim 1, use according to claims 2-4, or method according to claim 5, in which the bisphosphonate is an N-bisphosphonate.
8. A composition according to claim 1, use according to claims 2-4, or method according to claim 5, in which the bisphosphonate is a compound of formula I

- 23 -



wherein

X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C₁-C₄ alkyl, or alkanoyl;

R is hydrogen or C₁-C₄ alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles), or a pharmaceutically acceptable salt thereof or any hydrate thereof.

9. A composition according to claim 1, use according to claims 2-4, or method according to claim 5, in which the bisphosphonate is 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.
10. A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of an HMG-CoA reductase inhibitor.
11. A method according to claim 5 or claim 10, in which the HMG-CoA reductase inhibitor is a statin.
12. A method according to claim 11, in which the HMG-CoA reductase inhibitor is fluvastatin or a pharmaceutically acceptable salt of ester thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/09972

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/66 A61K31/405 A61P35/00 A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BERKHOUT T A ET AL: "THE NOVEL CHOLESTEROL-LOWERING DRUG SR-12813 INHIBITS CHOLESTEROL SYNTHESIS VIA AN INCREASED DEGRADATION OF 3-HYDROXY-3- METHYLGLUTARYL-COENZYME A REDUCTASE" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 24, 14 June 1996 (1996-06-14), pages 14376-14382, XP001026499 ISSN: 0021-9258 abstract; table 2	1,6
X	WO 99 45923 A (FISHER JOHN E ;MERCK & CO INC (US); RODAN GIDEON A (US)) 16 September 1999 (1999-09-16) claims 16-19	1,6-9

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

16 January 2004

Date of mailing of the international search report

30/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Greif, G

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/EP 03/09972

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2001/025028 A1 (FISHER JOHN E ET AL) 27 September 2001 (2001-09-27) claims 1-19 ---	1,6-9
X	US 2002/028826 A1 (CHEN BANG-CHI ET AL) 7 March 2002 (2002-03-07) Y abstract; claims 1,40 ---	10 2-5,11, 12
X	US 2002/061901 A1 (CHEN BANG-CHI ET AL) 23 May 2002 (2002-05-23) Y abstract; claims 1,39,40 ---	10 2-5,11, 12
X	WO 99 58505 A (WARNER LAMBERT CO ;LEOPOLD JUDITH (US); NEWTON ROGER SCHOFIELD (US) 18 November 1999 (1999-11-18) Y page 29, line 13-28 page 31, line 3-32; claims 1,22,23 ---	10,11 2-5,12
X	GARRETT I R ET AL: "STATINS AND BONE FORMATION" CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 7, no. 8, 2001, pages 715-736, XP008016599 ISSN: 1381-6128 Y page 715, left-hand column, paragraph 1 p.719, right column, "Effect on tumor cells" ---	10-12 2-5
X	GEBHARDT A ET AL: "EFFECTS OF PRAVASTATIN, A HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR, ON TWO HUMAN TUMOUR CELL LINES" JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 121, no. 6, 1995, pages 343-349, XP009010214 ISSN: 0171-5216 Y abstract; figure 1; table 1 ---	10,11 2-5,12
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/EP 03/09972

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEE S J ET AL: "Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 24 APR 1998, vol. 273, no. 17, 24 April 1998 (1998-04-24), pages 10618-10623, XP002267123 ISSN: 0021-9258 abstract	10,11
Y	page 10622, right-hand column, paragraph 2 ---	2-5,12
X	LARSSON O: "HMG-COA REDUCTASE INHIBITORS: ROLE IN NORMAL AND MALIGNANT CELLS" CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 3, no. 22, 1996, pages 197-212, XP001070345 ISSN: 1040-8428	10-12
Y	the whole document ---	2-5
X	WO 02 28270 A (SCHUMM BROOKE III ;KINDNESS GEORGE (US); PROBIOCHEM LLC (US); GUIL) 11 April 2002 (2002-04-11)	10,11
Y	abstract; claims 1,2 ---	2-5,12
Y	SANTINI D ET AL: "Pamidronate (P) induces modifications of circulating angiogenetic factors in cancer patients" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 37, April 2001 (2001-04), pages S262-S263, XP004478214 ISSN: 0959-8049 abstract	2-5
Y	WITTERS L ET AL: "Inhibition of growth of human breast cancer cell lines with the combination of zoledronic acid and a COX-2 inhibitor" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 37, April 2001 (2001-04), page S78 XP004477519 ISSN: 0959-8049 abstract --- -/--	2-5

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/EP 03/09972

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PECHERSTORFER M ET AL: "A randomized study of ibandronate and pamidronate in hypercalcemia of malignancy (HCM). Ibandronate is more effective in the subset of patients with severe HCM and has at least equal efficacy to pamidronate in HCM patients with less elevated baseline calcium levels"</p> <p>EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 37, April 2001 (2001-04), page S171 XP004477864 ISSN: 0959-8049 abstract</p> <p>---</p>	2-5
Y	<p>OURA S ET AL: "Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report"</p> <p>CANCERLIT, XP002232827 abstract</p> <p>---</p>	2-5
Y	<p>FREYER G ET AL: "Palliative hormone therapy, low dose chemotherapy and bisphosphonate in breast cancer patients with bone marrow involvement and pancytopenia; report of pilot experience"</p> <p>EUROPEAN JOURNAL OF INTERNAL MEDICINE, ELSEVIER, AMSTERDAM,, NL, vol. 11, 2000, pages 329-333, XP002257266 ISSN: 0953-6205 abstract</p> <p>---</p>	2-5
Y	<p>SHIPMAN C M ET AL: "BISPHOSPHONATES INDUCE APOPTOSIS IN HUMAN MYELOMA CELL LINES: A NOVEL ANTI-TUMOR ACTIVITY"</p> <p>BRITISH JOURNAL OF HAEMATOLOGY, OXFORD, GB, vol. 98, no. 3, September 1997 (1997-09), pages 665-672, XP008016800 ISSN: 0007-1048 abstract</p> <p>-----</p>	2-5

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/EP 03/09972

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9945923	A	16-09-1999	AU 2901199 A CA 2323448 A1 EP 1061917 A1 JP 2002506030 T WO 9945923 A1 US 2001025028 A1	27-09-1999 16-09-1999 27-12-2000 26-02-2002 16-09-1999 27-09-2001
US 2001025028	A1	27-09-2001	AU 2901199 A CA 2323448 A1 EP 1061917 A1 JP 2002506030 T WO 9945923 A1	27-09-1999 16-09-1999 27-12-2000 26-02-2002 16-09-1999
US 2002028826	A1	07-03-2002	US 2002061901 A1 AU 6686001 A BR 0111571 A CA 2412979 A1 CN 1436174 T CZ 20023931 A3 EP 1294696 A2 HU 0302955 A2 NO 20026011 A WO 0196311 A2	23-05-2002 24-12-2001 01-07-2003 20-12-2001 13-08-2003 12-03-2003 26-03-2003 29-12-2003 12-02-2003 20-12-2001
US 2002061901	A1	23-05-2002	US 2002028826 A1 AU 6686001 A BR 0111571 A CA 2412979 A1 CN 1436174 T CZ 20023931 A3 EP 1294696 A2 HU 0302955 A2 NO 20026011 A WO 0196311 A2	07-03-2002 24-12-2001 01-07-2003 20-12-2001 13-08-2003 12-03-2003 26-03-2003 29-12-2003 12-02-2003 20-12-2001
WO 9958505	A	18-11-1999	AU 758891 B2 AU 3979299 A BG 105003 A BR 9911785 A CA 2331295 A1 CN 1306515 T EE 200000660 A EP 1077949 A2 HR 20000771 A1 HU 0102322 A2 JP 2002514628 T NO 20005680 A NZ 508357 A PL 344662 A1 SK 16742000 A3 WO 9958505 A2 US 6492410 B1 ZA 200006491 A	03-04-2003 29-11-1999 31-07-2001 03-04-2001 18-11-1999 01-08-2001 15-04-2002 28-02-2001 30-06-2001 28-11-2001 21-05-2002 10-01-2001 27-09-2002 19-11-2001 10-07-2001 18-11-1999 10-12-2002 09-05-2002
WO 0228270	A	11-04-2002	US 2002086894 A1 AU 1305002 A WO 0228270 A2 WO 02094021 A1	04-07-2002 15-04-2002 11-04-2002 28-11-2002

International Publication No
PCT/EP 03/09972

Form PCT/ISA/210 (patent family annex) (July 1992)